Pay in 4 interest-free payments of $16.25 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
AZD-2281 was approved in 2014 for treating advanced ovarian cancer
and a decreased response to chemotherapy
13(9):1070-5
inhibits IgE/antigen-induced vascular hyperpermeability in a well-characterized murine model of passive cutaneous anaphylaxis
TZ9 - Rad6 Ubiquitin Inhibitor. CAS# 1002789-86-7 size:10mg solid AZD-2281 was approved in 2014TZ9, CAS No. 1002789 86 7, is a selective and cell permeable inhibitor of human E2 ubiquitin conjugating enzyme Rad6B. It binds to the Rad6B catalytic site, inhibits Rad6B induced histone H2A ubiquitination, downregulates intracellular catenin. It can induce G2 M arrest and apoptosis, and inhibit proliferation and migration of metastatic human breast cancer cells (IC50 ~6 M). Product information CAS Number: 1002789 86 7 Molecular Weight: 366. 33
US$ 55.00
US$ 37.00
US$ 104.00
US$ 70.00
US$ 144.50
US$ 39.00
US$ 229.00
US$ 99.00
US$ 63.00
US$ 74.00
US$ 56.00
US$ 37.00
US$ 69.50
US$ 47.00
US$ 38.00